FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Mehta Minesh 		2. Issuer Name and Ticker or Trading Symbol

PHARMACYCLICS INC [ PCYC ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/26/2015
(Street)

SUNNYVALE, CA 94085
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $2.30   5/26/2015     D         4000      (1) 9/10/2018   Common Stock   4000     (1) 0   D    
Stock Option (Right to Buy)   $14.26   5/26/2015     D         7500      (1) 12/15/2021   Common Stock   7500     (1) 0   D    
Stock Option (Right to Buy)   $28.47   5/26/2015     D         683      (1) 4/2/2022   Common Stock   683     (1) 0   D    
Stock Option (Right to Buy)   $59.28   5/26/2015     D         208      (1) 7/2/2022   Common Stock   208     (1) 0   D    
Stock Option (Right to Buy)   $65.56   5/26/2015     D         267      (1) 10/1/2022   Common Stock   267     (1) 0   D    
Stock Option (Right to Buy)   $49.00   5/26/2015     D         7500      (1) 11/9/2022   Common Stock   7500     (1) 0   D    
Stock Option (Right to Buy)   $61.44   5/26/2015     D         322      (1) 1/2/2023   Common Stock   322     (1) 0   D    
Stock Option (Right to Buy)   $79.67   5/26/2015     D         325      (1) 4/1/2023   Common Stock   325     (1) 0   D    
Stock Option (Right to Buy)   $74.48   5/26/2015     D         3750      (1) 5/9/2023   Common Stock   3750     (1) 0   D    
Stock Option (Right to Buy)   $85.39   5/26/2015     D         304      (1) 7/1/2023   Common Stock   304     (1) 0   D    
Stock Option (Right to Buy)   $139.89   5/26/2015     D         184      (1) 10/1/2023   Common Stock   184     (1) 0   D    
Stock Option (Right to Buy)   $108.44   5/26/2015     D         238      (1) 1/2/2024   Common Stock   238     (1) 0   D    
Stock Option (Right to Buy)   $107.42   5/26/2015     D         157      (1) 4/1/2024   Common Stock   157     (1) 0   D    
Stock Option (Right to Buy)   $95.08   5/26/2015     D         3750      (1) 5/9/2024   Common Stock   3750     (1) 0   D    
Stock Option (Right to Buy)   $89.58   5/26/2015     D         407      (1) 7/1/2024   Common Stock   407     (1) 0   D    
Stock Option (Right to Buy)   $115.80   5/26/2015     D         314      (1) 10/1/2024   Common Stock   314     (1) 0   D    
Stock Option (Right to Buy)   $124.46   5/26/2015     D         222      (1) 1/2/2025   Common Stock   222     (1) 0   D    
Stock Option (Right to Buy)   $257.015   5/26/2015     D         146      (1) 4/7/2025   Common Stock   146     (1) 0   D    

Explanation of Responses:
( 1)  Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Mehta Minesh
C/O PHARMACYCLICS, INC.
995 EAST ARQUES AVENUE
SUNNYVALE, CA 94085 		X



Signatures
/s/ Minesh Mehta 5/27/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
(MM) (NASDAQ:PCYC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more (MM) Charts.
(MM) (NASDAQ:PCYC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more (MM) Charts.